{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:03:55Z","timestamp":1785215035973,"version":"3.55.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Next-generation sequencing is optimal for testing advanced\/metastatic non\u2013small cell lung cancer (NSCLC) biomarkers; however, implementation and access are often hindered across Asia by turnaround time (TAT), logistics, and reimbursement. This study aimed to implement a multigene biomarker testing algorithm for the comprehensive detection of actionable NSCLC biomarkers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>The AmoyDx PLC Panel, a multigene polymerase chain reaction (PCR), was used in testing, with an optimal workflow developed in Chi Mei Medical Center, Taiwan. Tests were conducted on 897 NSCLC samples between June 2022 and November 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Among the tested samples, 83.0% were adenocarcinoma, with 74.4% at stage IV. Most samples were successfully analyzed for additional biomarkers, with 1.3% and 2.1% of samples having insufficient tissue or DNA quality, and insufficient RNA quality, respectively. This study reflected clinical reality, with most samples tested at initial diagnosis (72.0%). Other patients had previous single-gene testing for epidermal growth factor receptor (\n              <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n              )\/anaplastic lymphoma kinase (\n              <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n              )\/ROS proto-oncogene 1, receptor tyrosine kinase (\n              <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n              ) with negative results (11.2%), and others were tested after progression on tyrosine kinase inhibitors (16.8%). The median testing TAT was short (4 days). Of the patients tested at diagnosis (n = 638), 50.6% had\n              <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n              mutations and 79 (12.4%) patients had alterations in Kirsten RAat Sarcoma viral oncogene homolog (\n              <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n              ) G12C (2.4%), v-raf murine sarcoma viral oncogene homolog B1 (\n              <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n              ) (0.9%), human epidermal growth factor receptor 2 (\n              <jats:italic toggle=\"yes\">HER2<\/jats:italic>\n              ) (3.5%), mesenchymal-epithelial transition factor (\n              <jats:italic toggle=\"yes\">MET<\/jats:italic>\n              ) (2.4%),\n              <jats:italic toggle=\"yes\">ALK<\/jats:italic>\n              (1.3%),\n              <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n              (1.6%), and rearranged during transfection (\n              <jats:italic toggle=\"yes\">RET<\/jats:italic>\n              ) (0.5%). Among the 99 patients who had previously tested negative for\n              <jats:italic toggle=\"yes\">EGFR\/ALK\/ROS1<\/jats:italic>\n              , 47 (47.5%) patients had biomarker alterations that were potentially targetable by available drugs.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>This study highlighted the effectiveness of multigene PCR testing in identifying actionable NSCLC biomarkers for low failure rate, short TAT, and minimal tissue requirements, enabling timely, personalized interventions. The workflow implemented at Chi Mei Medical Center provides a model that other hospitals can adopt to overcome testing barriers and improve precision oncology access.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-25-00144","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:59:17Z","timestamp":1760558357000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Implementation of Real-World Diagnostic Strategies in Taiwan for the Identification of Targetable Oncogenic Driver Alterations in Non\u2013Small Cell Lung Cancer"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9403-2489","authenticated-orcid":false,"given":"Wan-Shan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"Department of Medical Technology, Chung Hwa University of Medical Technology, Tainan, Taiwan"},{"name":"Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yun","family":"Hung","sequence":"additional","affiliation":[{"name":"Trans-Omics Laboratory for Precision Medicine, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"Institute of Precision Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-6579","authenticated-orcid":true,"given":"Yu-Hsuan","family":"Kuo","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Science, Chia Nan University, Tainan, Taiwan"},{"name":"Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5902-7078","authenticated-orcid":false,"given":"Shu-Farn","family":"Tey","sequence":"additional","affiliation":[{"name":"Doctoral Program of Clinical and Experimental Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan"},{"name":"Division of Pulmonary Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7672-739X","authenticated-orcid":true,"given":"Rachel Yi-Chen","family":"Liu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9653-7432","authenticated-orcid":true,"given":"Connie Pei-Shan","family":"Hung","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe Lo-Ho","family":"Chen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M.","family":"Simon","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-7576","authenticated-orcid":false,"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Trans-Omics Laboratory for Precision Medicine, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan"},{"name":"National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2022.12.004"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-3"},{"key":"e_1_3_7_4_2","volume-title":"Health Promotion Administration (HPA)\u20142021 Health Promotion Administration Annual Report","author":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan","unstructured":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan: Health Promotion Administration (HPA)\u20142021 Health Promotion Administration Annual Report. https:\/\/www.hpa.gov.tw\/EngPages\/Detail.aspx?nodeid=1070&pid=14658"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100839"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100838"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.021"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.47700"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587"},{"key":"e_1_3_7_10_2","article-title":"Comprehensive genomic analysis of patients with non\u2013small-cell lung cancer using blood-based circulating tumor DNA assay: Findings from the BFAST database of a single center in Taiwan","author":"Wang HY","unstructured":"Wang HY, Ho CC, Lin YT, et al: Comprehensive genomic analysis of patients with non\u2013small-cell lung cancer using blood-based circulating tumor DNA assay: Findings from the BFAST database of a single center in Taiwan. JCO Precis Oncol 10.1200\/PO.23.00314","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_7_11_2","article-title":"Registry of genetic alterations of Taiwan non\u2013small cell lung cancer by comprehensive next-generation sequencing: A real-world cohort study-Taiwan Cooperative Oncology Group T1521","author":"Liao BC","unstructured":"Liao BC, Chiang NJ, Chang GC, et al: Registry of genetic alterations of Taiwan non\u2013small cell lung cancer by comprehensive next-generation sequencing: A real-world cohort study-Taiwan Cooperative Oncology Group T1521. JCO Glob Oncol 10.1200\/GO.24.00125","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030174"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101586"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.10.155"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.08.023"},{"key":"e_1_3_7_16_2","volume-title":"Starting from May 1st, the National Health Insurance (NHI) Payment Have Been Covering Next-Generation Sequencing for Solid Cancer and Leukemia as Part of Precision Medicine for Cancer Treatment, Benefitting over 20,000 Patients, National Health Insurance Administration","author":"Ministry of Health and Welfare","year":"2024","unstructured":"Ministry of Health and Welfare: Starting from May 1st, the National Health Insurance (NHI) Payment Have Been Covering Next-Generation Sequencing for Solid Cancer and Leukemia as Part of Precision Medicine for Cancer Treatment, Benefitting over 20,000 Patients, National Health Insurance Administration. Ministry of Health and Welfare, 2024. https:\/\/www.nhi.gov.tw\/en\/cp-15076-08d24-8-2.html"},{"key":"e_1_3_7_17_2","volume-title":"AmoyDx\u00ae Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for AUGTYRO\u00ae (Repotrectinib)","author":"Amoy Diagnostic","year":"2024","unstructured":"Amoy Diagnostic: AmoyDx\u00ae Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for AUGTYRO\u00ae (Repotrectinib). Amoydiagnostics, 2024. https:\/\/www.amoydiagnostics.com\/about\/press-releases\/250"},{"key":"e_1_3_7_18_2","volume-title":"AmoyDx\u00ae Pan Lung Cancer PCR Panel Receives China NMPA Approval","author":"Amoy Diagnostic","year":"2024","unstructured":"Amoy Diagnostic: AmoyDx\u00ae Pan Lung Cancer PCR Panel Receives China NMPA Approval. Amoydiagnostic, 2024. https:\/\/www.amoydiagnostics.com\/about\/press-releases\/247"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01831-6"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2017.01.011"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06123-3"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107886"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.873111"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8637"},{"key":"e_1_3_7_25_2","first-page":"156","article-title":"Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer","volume":"4","author":"Kohno T","year":"2015","unstructured":"Kohno T, Nakaoku T, Tsuta K, et al: Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 4:156-164, 2015","journal-title":"Transl Lung Cancer Res"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0318"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102602"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9338"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120852"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01104-6"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:59:25Z","timestamp":1760558365000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1200\/GO-25-00144"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00144","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500144"}}